Anti-VEGF Therapy for AMD: Results and Guidelines
Age-Related Macular Degeneration, Page: 233-245
2013
- 2Citations
- 7Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Three recent guidelines have addressed management of neovascular AMD (NV-AMD) with anti-VEGF agents, covering diagnosis, selection including classification of lesions as ‘active’ or ‘inactive’, and approaches to treatment with anti-VEGF agents, using monthly or flexible regimens. Most data from large randomised clinical trials has accumulated for ranibizumab therapy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84897565970&origin=inward; http://dx.doi.org/10.1007/978-3-642-22107-1_15; http://link.springer.com/10.1007/978-3-642-22107-1_15; http://link.springer.com/content/pdf/10.1007/978-3-642-22107-1_15.pdf; https://dx.doi.org/10.1007/978-3-642-22107-1_15; https://link.springer.com/chapter/10.1007/978-3-642-22107-1_15; http://www.springerlink.com/index/10.1007/978-3-642-22107-1_15; http://www.springerlink.com/index/pdf/10.1007/978-3-642-22107-1_15
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know